Table 1. Sulindac sulfide increases sensitivity of human tumor cell lines to doxorubicin.
| Histotype | Cell Line | IC50 (Dox only) | IC50 (+ 5 μM SS) |
| Breast | T47D | 0.080 | 0.045 |
| Breast | MCF-7 | 0.025 | 0.020 |
| Breast | HS578T | 0.421 | 0.217 |
| Breast | MDA-MB-468 | 0.128 | 0.140 |
| Breast | NCI-ADRRES | 6.337 | 5.884 |
| Breast | BT-549 | 0.201 | 0.112 |
| CNS | U-251 | 0.081 | 0.040 |
| CNS | SNB75 | 0.206 | 0.080 |
| CNS | SF-295 | 0.097 | 0.043 |
| CNS | SF-268 | 0.204 | 0.092 |
| CNS | SNB-19 | 0.035 | 0.015 |
| CNS | SF-539 | 0.142 | 0.091 |
| Colon | SW620 | 0.085 | 0.048 |
| Colon | COLO-205 | 0.031 | 0.022 |
| Colon | HCC-2998 | 0.186 | 0.127 |
| Colon | HCT-15 | 0.692 | 0.737 |
| Hematopoietic | K562 | 0.102 | 0.069 |
| Hematopoietic | SR | 0.003 | 0.002 |
| Hematopoietic | MOLT-4 | 0.005 | 0.004 |
| Hematopoietic | CCRF-CEM | 0.015 | 0.013 |
| Lung | HOP92 | 0.108 | 0.038 |
| Lung | NCI-H522 | 0.066 | 0.049 |
| Lung | NCI-H460 | 0.041 | 0.016 |
| Lung | NCI-H322M | 0.592 | 0.202 |
| Lung | A-549 | 0.065 | 0.029 |
| Lung | EKVX | 0.646 | 0.827 |
| Lung | NCI-H23 | 0.085 | 0.041 |
| Melanoma | SKMEL5 | 0.150 | 0.087 |
| Melanoma | MALME3M | 0.220 | 0.096 |
| Melanoma | LOX1-MV1 | 0.098 | 0.071 |
| Melanoma | M-14 | 0.241 | 0.113 |
| Melanoma | UACC-257 | 0.388 | 0.222 |
| Melanoma | UACC-62 | 0.163 | 0.086 |
| Melanoma | MDA-MB-435 | 0.378 | 0.135 |
| Ovarian | IGR-OV1 | 0.073 | 0.031 |
| Ovarian | OVCAR-3 | 0.299 | 0.121 |
| Ovarian | OVCAR-8 | 0.116 | 0.064 |
| Ovarian | OVCAR-4 | 0.984 | 0.439 |
| Ovarian | OVCAR-5 | 0.542 | 0.134 |
| Prostate | PC-3 | 0.429 | 0.162 |
| Prostate | DU-145 | 0.077 | 0.029 |
| Renal | TK10 | 0.183 | 0.093 |
| Renal | 786-0 | 0.086 | 0.046 |
| Renal | RXF-393 | 0.345 | 0.187 |
| Renal | U-031 | 0.592 | 0.393 |
| Renal | A-498 | 0.116 | 0.064 |
| Renal | ACHN | 0.042 | 0.018 |